AVTX Avalo Therapeutics
- 12.9000
- -0.3500-2.64%
Avalo Therapeutics News
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurati
Avalo Therapeutics Raised to Outperform From Perform by Oppenheimer
Avalo Therapeutics Raised to Outperform From Perform by Oppenheimer
Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target
Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 price target.
Avalo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 118.07% Oppenheimer → $35 Upgrades Perform → Outperform 06/27/2023 — Oppenheimer Downgrades Ou
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $
SOL, MESO and ACOR Among Pre-market Losers
Press Release: Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors.
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersGalera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, t
Friday Avalo Therapeutics Said Cash Balance Of $7.4M And Capital Raise Of $185M In March 2024 Is Expected To Provide Cash Runway Into 2027
Friday Avalo Therapeutics Said Cash Balance Of $7.4M And Capital Raise Of $185M In March 2024 Is Expected To Provide Cash Runway Into 2027
Avalo Therapeutics EPS of -$114.00, Revenue of $1.92M Beats by $0.72M
Press Release: Avalo Reports 2023 Financial Results and Provides Business Updates
Avalo Reports 2023 Financial Results and Provides Business Updates -- Acquired AVTX-009, Phase-2 ready anti-IL-1 mAb, in March 2024 -- Increased cash position with private placement financing i
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
Top Midday Gainers
Avalo Therapeutics (AVTX) shares skyrocketed amid heavy trading Thursday after the company completed the acquisition of privately held AlmataBio and said late Wednesday it entered into a private place
Trending Stocks Today: Avalo Therapeutics Shoots up 381.05%
March 28th - US stocks trending in regular trading hours.Gainers: $Avalo Therapeutics(AVTX.US)$ shoots up 381.05% to $22.85 with a turnover of $506.08 million. $Xilio Therapeutics(XLO.US)$ surges 130.
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE:REX) rose sharply during Thursday's session following upbeat quar
Micro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin Disorder
Avalo Therapeutics Inc (NASDAQ:AVTX) shares are skyrocketing as the company on Wednesday announced the acquisition of a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio Inc.
Avalo Therapeutics Soars Over 260% After It Acquire AlmataBio For Skin Inflammatory Drug
Market-Moving News for March 28th
AVTX: 406% | Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionXLO: 399% | Xilio Therapeutics shares are trading higher after the company announced an exclus
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data
US stock futures were little changed in Thursday's premarket activity ahead of a slew of economic data coming out this morning, including GDP, initial jobless claims, and consumer sentiment reports, a
Analysis
Price Target
No Data
